This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects.
Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...
This morning Otsuka America, a subsidiary of the Japanese pharma company, announced that it is teaming up with Click Therapeutics, maker of software as a prescription medical treatment, to create a new digital therapeutic to treat major depressive disorder (MDD).
The goal of the partnership is to develop a software app that will employ cognitive therapy principles and can be used either with or...
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space.
“These technologies have a tremendous opportunity to...
Correction: An earlier version of this article was unclear about differences between Abilify MyCite and the Proteus Digital Medicine Platform.
Earlier this week, Proteus Digital Health and Otsuka Pharmaceuticals announced that Abilify MyCite, a new, sensor-enabled version of Otsuka’s drug for schizophrenia, had received FDA approval for mental health conditions including schizophrenia and...
The first drug in the US with a digital ingestion tracking system has been approved by the FDA.
The pill, Abilify MyCite, is prescribed for treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and as an add-on treatment for depression in adults.
An ingestible sensor embedded in the pill is able to record that the medication was taken – sending...
Health2047, the American Medical Association-backed technology innovation enterprise, is working with pharma company Celgene to create a new healthcare information transfer system. As part of the deal, Health2047 is developing a new data transfer protocol for healthcare, focused on security, trustworthiness, and connectivity. More.
...
Samsung recently announced two interesting partnerships...
Otsuka, the Japanese pharma company that makes the antipsychotic drug Abilify, has partnered with Australian digital health company Medibio to use Medibio’s system to assess the efficacy of its flagship product.
Medibio uses wearable-derived data about heart rate, motion, and sleep to create objective biomarkers for mental illness.
“We have proprietary algorithms and technology that use circadian...
Redwood City, California-based Proteus Digital Health announced plans this week to open its first international digital medicine manufacturing plant in the United Kingdom along with partnerships with various arms of the UK's National Health Service (NHS) to validate its "smart pill" system. The NHS-affiliated groups that inked partnerships with Proteus this week include Eastern Academic Health...
Proteus Biomedical's Raisin system
Redwood City, California-based Proteus Digital Health announced that it had raised $62.5 million in its latest round of funding led by Oracle with participation from existing investors Otsuka, Novartis, Sino Portfolio and others. MobiHealthNews reported on the first $17.5 million that Proteus raised for this round a year ago, so the $62.5 million includes an...
